

Case Study 4:

Out-licensing out of transdermal patch technologies for delivery of large molecule immunotherapies

Situation:

Each year in the US alone, there are 29,000 anaphylactic reactions to foods treated in emergency departments and nearly 200 deaths due to food allergies. Seafood allergies are the most common cause of food allergy with life-threatening reactions. Traditionally, anti-allergy or tolerising reagents are injected into patients but more direct access to immune system is preferred.

Approach (through NanoVentures Australia):

Negotiated with an immunotherapeutics Company, to enter into a co-development and licensing Agreement. Focused on the evaluation and animal testing of a combined approach; the use of the Companies formulation with NVA's Transdermal Patches, for delivery of anti-allergy therapeutic(s).

Result:

Successful Agreement negotiation and execution, followed by coordination of the resulting activities between NVA's partners and the Company, for evaluation and testing of the materials and reagents with the patch delivery system.

